Strategic collaborations Fannin partners with Texas Medical Center institutions to co-found and actively manage startup companies, indicating a ready-made channel for joint ventures, licensing deals, and co-development arrangements with academic spinouts and translational research projects.

SBIR driven funding Recent and ongoing SBIR grants and Phase II/Phase I funding activity (including NEI and NCI) signal ongoing government-backed capital opportunities to fund joint development programs, which could be leveraged for co-development contracts and milestone-based partnerships.

Portfolio expansion With a validated model targeting the addition of 15-20 portfolio companies over 3-5 years, there is a growing need for infrastructure, services, and capital partnerships to scale operations, creating opportunities for contracted CRO, regulatory support, and go-to-market services.

Key personnel access The recruitment of experienced executives (e.g., immunology drug developers and industry veterans) suggests potential for advisory/funded leadership roles in partner ventures, as well as strategic co-investments and executive search collaborations.

Early-stage monetization Fannin provides central office space, seed capital, and an extensive resource network to startups, indicating opportunities to offer shared services, incubator-style programs, or scalable commercialization services (training, regulatory affairs, IP strategy) as a revenue-generating partner.